Renal clearance, a crucial parameter in pharmacokinetics, can be determined using two different methods: the graphical method and the midpoint method. These methods provide insights into the rate of drug excretion by the kidneys and aid in assessing renal function.

The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a larger excretion rate and a steeper slope on the graph, corresponding to a greater renal clearance. Conversely, slowly excreted drugs display a smaller slope, indicating a lower renal clearance.

The clearance equation can be rearranged and integrated to obtain the cumulative amount of drug excreted in the urine. The renal clearance can be determined by plotting this graph and analyzing its slope. However, one disadvantage of the graphical method is that if a data point is missing or incomplete, it is difficult to accurately calculate the cumulative drug amount excreted in urine.

Alternatively, the midpoint method can be used to calculate renal clearance. This method uses the plasma drug concentration at the midpoint of the collection interval. Although the midpoint method is less robust than the graphical method, it is clinically used when only a limited number of plasma drug concentrations can be collected and measured. This allows for estimating renal clearance based on the available data points.

Both methods play a significant role in assessing renal clearance and evaluating renal function. The graphical method provides a more detailed analysis, while the midpoint method offers a practical alternative when limited data is available for analysis.

It is worth noting that these methods are just two of several approaches used to determine renal clearance. Healthcare professionals rely on these techniques to make informed decisions regarding drug dosing and ensuring safe and effective therapy, particularly in patients with renal impairment.

Из главы 6:

article

Now Playing

6.22 : Determination of Renal Drug Clearance: Graphical and Midpoint Methods

Pharmacokinetics: Drug Excretion and Clearance

24 Просмотры

article

6.1 : Элиминация наркотиков: обзор

Pharmacokinetics: Drug Excretion and Clearance

35 Просмотры

article

6.2 : Кинетика элиминации: первого и нулевого порядка

Pharmacokinetics: Drug Excretion and Clearance

42 Просмотры

article

6.3 : Почечная экскреция лекарственных препаратов: обзор

Pharmacokinetics: Drug Excretion and Clearance

28 Просмотры

article

6.4 : Почечное выведение лекарственных препаратов: клубочковая фильтрация

Pharmacokinetics: Drug Excretion and Clearance

35 Просмотры

article

6.5 : Почечная экскреция лекарственных препаратов: канальцевая реабсорбция

Pharmacokinetics: Drug Excretion and Clearance

18 Просмотры

article

6.6 : Почечная экскреция: канальцевая секреция

Pharmacokinetics: Drug Excretion and Clearance

17 Просмотры

article

6.7 : Почечная экскреция лекарственных средств: влияние рН мочи, скорости потока и рКАпрепарата

Pharmacokinetics: Drug Excretion and Clearance

30 Просмотры

article

6.8 : Выведение препаратов из печени: энтерогептический цикл

Pharmacokinetics: Drug Excretion and Clearance

18 Просмотры

article

6.9 : Выведение лекарств из печени: влияющие факторы

Pharmacokinetics: Drug Excretion and Clearance

20 Просмотры

article

6.10 : Выведение лекарственных препаратов: легочный и железистый пути

Pharmacokinetics: Drug Excretion and Clearance

10 Просмотры

article

6.11 : Выведение наркотиков: разные пути

Pharmacokinetics: Drug Excretion and Clearance

8 Просмотры

article

6.12 : Допуск к лекарствам: обзор

Pharmacokinetics: Drug Excretion and Clearance

13 Просмотры

article

6.13 : Модели клиренса: физиологические модели

Pharmacokinetics: Drug Excretion and Clearance

26 Просмотры

article

6.14 : Модели с зазорами: Модели отсеков

Pharmacokinetics: Drug Excretion and Clearance

22 Просмотры

See More

JoVE Logo

Исследования

Образование

О JoVE

Авторские права © 2025 MyJoVE Corporation. Все права защищены